Glaucoma, Parkinson's disease and neurodegeneration

被引:0
|
作者
Balci, Sevcan Yildiz [1 ]
Eraslan, Muhsin [2 ]
Temel, Ahmet [2 ]
机构
[1] Igdir Devlet Hastanesi, Oftalmol Klin, Igdir, Turkey
[2] Marmara Univ, Tip Fak Hastanesi, Oftalmol Anabilim Dali, Ust Kaynarca, Pendik, Turkey
来源
MARMARA MEDICAL JOURNAL | 2015年 / 28卷 / 01期
关键词
Irreversible vision loss; Neurodegenerative disorders; Neuroprotective therapy;
D O I
10.5472/MMJ.2015.03691.1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glaucoma is a disease that causes irreversible vision loss characterized by progressive retinal ganglion cell (RGC) death. The mechanisms independent of intraocular pressure are also implicated in glaucomatous degeneration pathogenesis and numerous similarities exist between glaucoma and neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. Although, there is a common pathway between glaucoma and neurodegenerative disorders, pathogenesis of the relationship between neurodegenerative disorders and glaucoma remains poorly undefined. Optical coherence tomography (OCT), non-invasively quantifies the thickness of the retinal nerve fiber layer (RNFL) which is effected due to RGC damage in glaucomatous patients. Recently, RNFL thickness measurements have been studied by using OCT in several neurodegenerative conditions, including Parkinson's disease. The RNFL is unique as a model of neurodegeneration where the changes in its structure is represented with axonal damage. RNFL thickness measurements are important in neurodegenerative disorders which are characterized with neuronal loss and have common pathogenesis with glaucoma. In this review, we emphasize the relationship between glaucoma, Parkinson's disease and neurodegeneration.
引用
收藏
页码:8 / 12
页数:5
相关论文
共 50 条
  • [21] Neurodegeneration and Neuroregeneration in Experimental Parkinson's Disease
    Blandini, F.
    Cova, L.
    Armentero, M. -T.
    Bossolasco, P.
    Polli, E.
    Nappi, G.
    Silani, V.
    CELL TRANSPLANTATION, 2010, 19 (03) : 332 - 333
  • [22] CSF markers of neurodegeneration in Parkinson's disease
    Vranova, Hana Prikrylova
    Mares, Jan
    Nevrly, Martin
    Stejskal, David
    Zapletalova, Jana
    Hlustik, Petr
    Kanovsky, Petr
    JOURNAL OF NEURAL TRANSMISSION, 2010, 117 (10) : 1177 - 1181
  • [23] Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease
    Gelders, Geraldine
    Baekelandt, Veerle
    Van der Perren, Anke
    JOURNAL OF IMMUNOLOGY RESEARCH, 2018, 2018
  • [24] Calpain Mediated Neurodegeneration in Parkinson’s disease
    V. H. Knaryan
    Neurochemical Journal, 2023, 17 : 632 - 638
  • [25] CSF markers of neurodegeneration in Parkinson’s disease
    Hana Přikrylová Vranová
    Jan Mareš
    Martin Nevrlý
    David Stejskal
    Jana Zapletalová
    Petr Hluštík
    Petr Kaňovský
    Journal of Neural Transmission, 2010, 117 : 1177 - 1181
  • [26] PET assessment of neurodegeneration in Parkinson's disease
    de la Fuente-Fernandez, R.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S27 - S27
  • [27] Shared Mechanisms of Neurodegeneration in Alzheimer's Disease and Parkinson's Disease
    Xie, Anmu
    Gao, Jing
    Xu, Lin
    Meng, Dongmei
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [28] COX-2 and neurodegeneration in Parkinson's disease
    Teismann, P
    Vila, M
    Choi, DK
    Tieu, K
    Wu, DC
    Jackson-Lewis, V
    Przedborski, S
    PARKINSON'S DISEASE: THE LIFE CYCLE OF THE DOPAMINE NEURON, 2003, 991 : 272 - 277
  • [29] Angiogenin and tRNA fragments in Parkinson’s disease and neurodegeneration
    Jochen H M Prehn
    Elisabeth Jirström
    Acta Pharmacologica Sinica, 2020, 41 : 442 - 446
  • [30] Neurodegeneration in Parkinson's Disease: Genetics Enlightens Physiopathology
    Corti, Olga
    Fournier, Margot
    Brice, Alexis
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 2009, (73): : 215 - 221